ストックスクリーナーアプリを入手
10.69
1.14%
0.12
アフターアワーズ：
10.90
0.21
+1.96%
Telix Pharmaceuticals Ltd Adr (TLX) 最新ニュース
Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth - GlobeNewswire Inc.
Kinzey Capital Management Signals Telix ITM Deal Impact - The Globe and Mail
Telix Director David Gill Boosts Nasdaq ADS Stake - The Globe and Mail
Telix Pharmaceuticals Director David Gill Acquires 11,800 ADS on Nasdaq - kalkine.com.au
Telix Pharmaceuticals Applies to Quote 1,645 Shares Issued Under Employee Stock Purchase Plan - kalkine.com.au
Telix announces acquisition of ITM to create a global radiopharmaceutical powerhouse - BiotechDispatch
Telix (TLX) lines up US$1.65B cancer drug merger—and a big revenue jump - Stock Titan
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion - Yahoo! Finance Canada
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion - finance.yahoo.com
Telix to acquire ITM in deal worth up to $2.35bn - Pharmaceutical Technology
Telix Strikes $1.65 Billion Deal to Acquire Germany's ITM, Building a Radiopharmaceutical Powerhouse - finance.biggo.com
Health Check: Telix strikes monster $3.3 billion merger deal to form radiopharma giant - Stockhead
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse - GlobeNewswire Inc.
Telix Pharmaceuticals to Merge with ITM Isotope Technologies Munich SE, Forming Advanced Radiopharmaceutical Leader - Kalkine Media
Telix Pharmaceuticals Announces Combination with ITM Isotope Technologies Munich SE - Kalkine
Telix Pharmaceuticals Applies to Quote 108,080 Shares Issued Under Employee Share Plans - Kalkine
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD - investing.com
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Canada
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com UK
Two New York conferences will include Telix presentations - Stock Titan
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway - finance.yahoo.com
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com India
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Australia
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Canada
Telix Pharmaceuticals stock jumps on trial completion, FDA path - Investing.com
Up to 75% of prostate biopsies are negative. Telix enrolled 350 patients. - Stock Titan
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline - PR Newswire
Earnings call transcript: Telix H1 2026 profit jumps as guidance holds - Investing.com
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline - TradingView
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
Telix Schedules Aug. 20 Webcast for Half-Year Results - Stock Titan
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - Yahoo Finance
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Why Is Telix Pharmaceuticals (ASX:TLX) on Investors' Radar Despite a 30% One-Year Decline? - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
FDA Alignment to Advance ProstACT Global Phase 3 Trial - GlobeNewswire Inc.
Telix clears FDA protocol review for prostate cancer trial expansion - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
0.96%
大文字化:
|
ボリューム (24 時間):